PMDA Pharmaceutical Advertising: How to Review Drug and Medical Device Marketing in Japan
Japan's PMDA and PMD Act strictly regulate pharmaceutical advertising. Learn how to review drug and medical device marketing content for Japanese compliance.
The Pharmaceuticals and Medical Devices Agency (PMDA) and the Ministry of Health, Labour and Welfare (MHLW) jointly regulate pharmaceutical and medical device advertising in Japan through the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices (PMD Act, commonly known as the Pharmaceutical Affairs Act) and its implementing regulations. Japan's pharmaceutical advertising framework is among the most restrictive in Asia, with additional self-regulatory standards from the Japan Pharmaceutical Manufacturers Association (JPMA) and the Fair Trade Council of the Ethical Pharmaceutical Drugs Marketing Industry.
Violations can result in administrative orders, marketing authorization suspension, and criminal penalties. For pharmaceutical companies, medical device manufacturers, and healthcare organizations, the content of every promotional material must be reviewed against multiple layers of regulation before reaching any audience.
The Regulatory Framework
Key Regulations
| Regulation | Scope | Content Requirements |
|---|---|---|
| PMD Act Articles 66-68 | All pharmaceutical and medical device advertising | Prohibition on false/exaggerated claims, restriction on disease-specific advertising |
| MHLW Advertising Standards | Detailed advertising content rules | Specific requirements for claims, disclaimers, and visual representations |
| JPMA Code of Practice | Ethical drug industry | Self-regulatory standards for pharmaceutical promotion to healthcare professionals |
| Fair Competition Code | Ethical drugs | Restrictions on promotional activities, gifts, and incentives |
| Medical Device Advertising Standards | Medical device marketing | CE-marking equivalent (PMDA approval) reference requirements |
| Health Promotion Act | Health foods and supplements | Health claim restrictions, nutritional labeling |
PMD Act Advertising Provisions
The PMD Act contains three fundamental advertising restrictions:
Article 66 — False or exaggerated advertising: No person shall advertise a drug, medical device, or cosmetic with claims that are false or exaggerated regarding its name, manufacturing method, efficacy, effects, or performance.
Article 67 — Restrictions on specific disease advertising: The MHLW can restrict advertising for drugs used to treat specific diseases (cancer, certain infectious diseases) to prevent inappropriate self-medication.
Article 68 — Unapproved product advertising: No person shall advertise drugs, medical devices, or cosmetics that have not received marketing approval.
Common Pharmaceutical Advertising Compliance Issues
1. Prescription Drug Promotion
In Japan, prescription drug advertising to the general public is strictly limited:
- Direct-to-consumer advertising of prescription drugs is effectively prohibited (unlike the US)
- Disease awareness campaigns must not implicitly promote a specific prescription product
- The drug name, indication, and manufacturer may appear in directories and reference materials
- Promotional activities are limited to healthcare professionals (HCPs)
For HCP-directed promotion:
- Claims must be based on the approved product labeling (tenpu-bunsho)
- Off-label promotion is prohibited
- Clinical data cited must be from approved clinical studies
- Comparative claims must use appropriate study design and methodology
- Gifts, entertainment, and hospitality are restricted under the Fair Competition Code
2. OTC Drug Advertising
Over-the-counter drug advertising to consumers is permitted but must:
- Include the product name, manufacturer, and marketing authorization holder
- State the approved indications only — no expanded claims
- Include "Please read the enclosed document carefully" advisory
- Include risk information proportionate to the product category
- Not use before-and-after representations that guarantee outcomes
- Not feature endorsements by healthcare professionals that imply guaranteed efficacy
3. Medical Device Advertising
Medical device advertising must reference:
- The PMDA-approved intended use — no expanded indications
- The device classification and approval number
- Risk disclosures appropriate to the device class
- Manufacturer and marketing authorization holder information
- No testimonials suggesting guaranteed outcomes
4. Health Food and Supplement Claims
Japan has a unique regulatory category for health foods:
| Category | Claim Type Permitted | Review Required |
|---|---|---|
| Foods for Specified Health Uses (TOKUHO) | Specific health claims approved by MHLW | Government approval required |
| Foods with Function Claims (Kinosei Hyoji Shokuhin) | Self-reported function claims | Notification to Consumer Affairs Agency |
| Foods with Nutrient Function Claims | Standard nutrient function statements | No specific approval needed |
| General health foods | No health claims permitted | Cannot imply health benefits |
A Pharmaceutical Advertising Review Checklist
- Product has valid PMDA marketing authorization
- Claims match the approved product labeling (tenpu-bunsho)
- No public advertising for prescription-only drugs
- OTC ads include mandatory "read the enclosed document" advisory
- Risk information is proportionate to the product category
- No off-label claims or expanded indications
- Clinical data cited is from approved studies with accurate methodology
- Comparative claims use appropriate study design
- No guaranteed outcome testimonials
- Healthcare professional endorsements do not imply guaranteed efficacy
- Medical device advertising references approved intended use only
- Health food claims match the regulatory category (TOKUHO, Function Claims, etc.)
- No disease treatment or cure claims for health foods
- Content is in accurate Japanese with correct medical terminology
- Fair Competition Code compliance for HCP-directed materials
Building a Pharmaceutical Content Review Process
Pharmaceutical and medical device companies operating in Japan should implement:
- Product classification: Determine the regulatory category and applicable advertising rules
- Label verification: Cross-check all claims against the approved product labeling
- Pre-publication compliance review: AI-assisted scanning for off-label claims, missing disclaimers, and prohibited advertising elements
- JPMA Code review: Check HCP-directed materials against self-regulatory standards
- Post-publication monitoring: Monitor for regulatory inquiries and competitor challenges
TeamBench enables pharmaceutical and medical device companies to build PMDA-specific content reviewers that evaluate promotional materials against Japanese regulatory standards. Custom criteria can check label compliance, claim permissibility, disclaimer presence, and advertising category restrictions — catching violations before they reach the market.
In Japan's highly regulated pharmaceutical market, where the distinction between permissible and prohibited advertising is precise, systematic content review is essential for both compliance and market access.